ORBIMED ADVISORS LLC
"13F equity value" = market value of this filer's US-listed long equity positions only. It excludes cash, bonds, non-US and short positions, so it understates a fund's true assets under management — often by a lot.
13F holdings are disclosed ~45 days after quarter-end, and they never reveal when within the quarter a fund actually bought. So any 13F-based summary is structurally late and blurred — this applies to every fund, including this one.
We backtested copying it anyway. Buying this fund's new positions the day each filing went public, over 32 quarters, returned +4.1% per quarter — versus +2.7% per quarter from simply owning every 13F stock. It beat that baseline in only 46.9% of quarters (excess t = 0.67, not statistically significant). Its filings tell you what it bought — not what you should buy.
Quarterly compounding, invested quarters only · entry 47 days after quarter-end (when 13F data becomes public)
Top 20 holdings of 107 · 2026 Q1
| Ticker | Value | Weight | QoQ |
|---|---|---|---|
| EWTX | $489M | | HOLD |
| ELVN | $312M | | HOLD |
| LLY | $218M | | TRIM |
| BSX | $149M | | HOLD |
| SION | $142M | | HOLD |
| AZN | $132M | | NEW |
| MYGN | $123M | | NEW |
| MBX | $109M | | TRIM |
| CRVS | $105M | | HOLD |
| ARGX | $100M | | TRIM |
| EW | $99M | | TRIM |
| ISRG | $96M | | TRIM |
| CMPX | $81M | | HOLD |
| MRK | $80M | | NEW |
| GPCR | $71M | | ADD |
| AVBP | $70M | | HOLD |
| IRON | $68M | | HOLD |
| SPRY | $67M | | HOLD |
| CGON | $64M | | TRIM |
| XENE | $62M | | ADD |
QoQ vs previous quarter's share count · NEW = new position · ADD/TRIM = ±2% shares · HOLD = unchanged.
New positions in 2026 Q1
Method & Limitations
Method: a "new position" = held this quarter, absent last quarter (options excluded; stocks with <50 prior holders excluded to filter spin-off artifacts). Entry 47 days after quarter-end — the first day the public could act on the filing. Benchmark = equal-weighted universe of all 13F-held stocks. Limitations: quarterly snapshots can't see intra-quarter trades; survivorship bias — funds that shut down are absent, which flatters the sample. Statistics, not advice.